The KEYNOTE-024 trial used pembrolizumab (a monoclonal antibody against programmed death 1) in patients with advanced<unk> -small cell lung cancer and PD-L1 expression. Pembrolizumab was associated with significantly longer progression-free and overall survival. The reported adverse events were lower than those of platinum-based chemotherapy.
Non small cell lung cancer future or investigational therapies
Pulmonary nodule future or investigational therapies
Small cell carcinoma of the lung medical therapy
Non small cell lung cancer medical therapy
Squamous cell carcinoma of the lung medical therapy
Large cell carcinoma of the lung medical therapy
Non small cell lung cancer chemotherapy
Non small cell lung cancer radiation therapy